Antiviral therapy: Quo vadis?

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1049-1053

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; DENGUE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; DENGUE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; ORTHOMYXOVIRIDAE INFECTIONS; VIRUSES;

EID: 77954686776     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.22     Document Type: Editorial

References (25)

1. Popovic M, Sarin PS, Rubert-Gurroff M et al. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 219, 856-859 (1983) (Pubitemid 13194772)
2. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
3. Vahlne A. A historical reflection on the discovery of human retroviruses. Retrovirology 6, 40 (2009).
4. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33, 307-320 (2009).
5. De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol. 19, 287-299 (2009).
6. Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta 32, 295-296 (1959).
7. De Clercq E. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago: an historical perspective. Adv. Virus Res. 73, 1-53 (2009).
8. Mitsuya H, Weinhold KJ, Furman PA et al. 3′-azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphot ropic virus type III/ lymphadenopathy- associated virus in vitro. Proc. Natl Acad. Sci. USA 82, 7096-7100 (1985).
9. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85, 1-18 (2010).
10. Martin JC, Hitchcock MJM, De Clercq E, Prusoff WH. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxy-nucleosides. Antiviral Res. 85, 34-38 (2010).
11. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85, 39-58 (2010).
12. De Clercq E. Tenofovir disoproxil fumarate (TDF): discovery and clinical development. In: Antiviral Drugs: Biology, Chemistry, Clinic, Kazmierski WM (Ed.). John Wiley & Sons, Inc (2010) (In Press).
13. de Bethune M-P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 85, 75-90 (2010).
14. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 85, 101-118 (2010).
15. Perry CM, Simpson D. Tenofovir disoproxil fumarate in chronic hepatitis B. Drugs 69, 2245-2256 (2009).
16. Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther. Clin. Risk Manag. 5, 177-185 (2009).
17. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442-2455 (2008).
18. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim H, Houghton M. The way forward in HCV treatment - finding the right path. Nature Rev. DrugDiscov. 6, 991-1000 (2007).
19. De Clercq E. The design of drugs for HIV and HCV. Nature Rev. Drug Discov. 6, 1001-1018 (2007).
20. De Clercq E. Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med. Res. Rev. 29, 571-610 (2009).
21. De Clercq E. Antiviral agents active against influenza A viruses. Nature Rev. Drug Discov. 5, 1015-1025 (2006).
22. von Itzstein M. The war against influenza: Discovery and development of sialidase inhibitors. Nature Rev. Drug Discov. 6, 967-974 (2007).
23. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360, 2605-2615 (2009).
24. Shinde V, Bridges CB, Uyeki TM et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N. Engl. J. Med. 360, 2616-2625 (2009).
25. Stevens AJ, Gahan ME, Mahalingam S, Keller PA. The medicinal chemistry of dengue fever. J. Med. Chem. 52, 7911-7926 (2009).